Migraine Therapeutics Patent Landscape Analysis Report 2026 Edition

Migraine Therapeutics Market Size, Growth Trends, and Industry Outlook

The growth is driven by the rising incidence of migraine across the globe. It affects roughly 1 billion people worldwide and ranks among the leading causes of years lived with disability in adults under 50. Demand rises as CGRP-targeted preventives reach patients who previously failed topiramate, propranolol or amitriptyline.

North America leads revenue, supported by early adoption of CGRP antibodies and gepants after the 2018 and 2019 US approvals. Europe follows, with reimbursement tied to failure of prior preventives, while Asia Pacific records the fastest uptake as China and Japan add CGRP products and local filers.

Commercial depth is visible in the product set. Four CGRP antibodies (Aimovig, Ajovy, Emgality, Vyepti), three oral gepants and the intranasal gepant zavegepant (approved in 2023) now give prescribers options across acute and preventive use. Neuromodulation devices from Theranica, electroCore and Cefaly add non-drug choices with FDA clearance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Migraine Therapeutics Patent Filing Trends and Innovation Activity

Patent filings in migraine therapeutics rose sharply after the 2018 launch wave. Early families covered antibody sequences and small-molecule CGRP antagonists, and later filings moved to formulations, salt forms, dosing regimens and combination use with acute drugs.

The dataset holds more than 4,000 patent families, with peak filing years between 2019 and 2023. Recent filings add PACAP-pathway antibodies, long-acting CGRP biologics, intranasal powders and wearable neuromodulation.

High unmet need among the roughly 40% of patients who discontinue first-generation preventives channels R&D spend into new mechanisms and delivery formats, which shows up directly as new filings.

Scope of the Migraine Therapeutics Patent Landscape Analysis Report

The report covers patent families, granted patents and pending applications related to migraine prevention and acute treatment. Coverage spans CGRP ligand and receptor antibodies, gepants, ditans, triptans, PACAP-targeting antibodies, delivery systems and neuromodulation devices.

Analysis includes filing and grant trends, assignee rankings, jurisdictional distribution, technology clusters, legal status and expiry profiles. Cluster-level views separate composition-of-matter claims from formulation, device and method-of-use claims.

Entities assessed include originator pharmaceutical companies, biotechnology developers, medical device makers, universities and research institutes, and generic and specialty formulation firms.

Global Migraine Therapeutics Patent Landscape Analysis

Migraine Therapeutics Patent Filing Trend Analysis

Annual patent family filings grew at an estimated 7% to 9% from 2020 to 2024. Growth came from follow-on CGRP formulations, paediatric and adolescent regimens, and a wave of new-mechanism programmes.

Grant volumes in 2025 exceeded 400 patents, led by US and Chinese offices. Filings on PACAP antibodies and intranasal systems grew faster than the overall average, while triptan filings stayed steady and concentrated in formulation improvements.

Leading Companies and Assignee Analysis in the Migraine Therapeutics Patent Landscape

Geographic Analysis of Migraine Therapeutics Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads in filings, driven by the large branded market and PCT national-phase entries. China ranks second, with rapid growth in domestic CGRP and gepant programmes, and Europe follows through the European Patent Office and national filings.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Migraine Therapeutics Technology Segmentation and Innovation Areas

The technology segments covered in the report include:

• CGRP monoclonal antibodies targeting ligand and receptor
• Gepants and oral CGRP receptor antagonists
• Ditans and 5-HT1F agonists
• Intranasal and orally disintegrating delivery systems
• PACAP-targeting antibodies and neuromodulation devices

Among these, CGRP-pathway antibodies and gepants hold the largest share of patent families.

Competitive Landscape and Emerging Trends in the Migraine Therapeutics Market

AbbVie, Eli Lilly, Amgen, Teva and Pfizer account for the largest portfolios. Amgen and Novartis co-developed Aimovig, Teva holds Ajovy (fremanezumab), and Pfizer owns Nurtec ODT and Zavzpret through the 2022 Biohaven acquisition. Lundbeck markets Vyepti (eptinezumab) and runs a PACAP antibody programme in phase 2.

Companies are focusing on:

• CGRP ligand and receptor antibody sequences
• Gepant composition and polymorph claims
• Orally disintegrating and nasal spray formulations
• Dosing interval and autoinjector claims
• PACAP and PAC1 receptor antibodies
• Paediatric and adolescent methods of use
• Wearable and remote electrical neuromodulation devices

Emerging innovation themes include PACAP-ligand antibodies such as Lundbeck's Lu AG09222, long-acting CGRP biologics, amylin receptor antagonists, nasal powder gepants, and closed-loop neuromodulation paired with smartphone applications. Combination use of antibodies with gepants is also drawing new method claims.

Strategic Insights from the Migraine Therapeutics Patent Landscape

The field combines a few large originators with mid-size specialists and fast-rising Chinese developers. Patent expiry for first-generation CGRP antibodies approaches in the early 2030s, which raises interest in biosimilar entry and lifecycle filings.

Technology segments, assignee positions and jurisdictional trends are tracked across the full patent set. The report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Migraine Therapeutics Patent Landscape Analysis

Patent data was collected from the USPTO, EPO, WIPO PATENTSCOPE, CNIPA, JPO and KIPO databases, with family consolidation by priority date. Queries combined CPC and IPC classes A61K 39/395, A61K 31/00, A61P 25/06, C07K 16/28 and A61N 1/36 with keywords for CGRP, PACAP, gepant and migraine.

Records were screened manually to remove tension-type, cluster-only and unrelated pain filings. Legal status, assignee names and expiry dates were normalised, and patents were grouped into drug class, treatment approach and delivery route.

Market data draws on regulatory filings from the FDA, EMA and PMDA, company disclosures, clinical trial registries and peer-reviewed literature. Market estimates are analyst figures aligned to the report forecast.

Related Reports

Chronic Migraine Epidemiology Forecast

Migraine Pipeline Analysis Report

Neurology Drugs Market